Skip to main content

Table 1 Demographic characteristics of the three groups

From: Efficacy and safety of ciprofol for gastroscopy in patients with obesity: a randomised clinical controlled trial using different weight-based dosing scales

 

Group T

(n = 36)

Group I

(n = 38)

Group L

(n = 34)

P value

Age (years)

46.69 ± 12.45

46.84 ± 11.82

43.88 ± 11.89

0.514

Sex:

   

0.711

Men, n (%)

30 (83.33)

29 (76.32)

28 (82.35)

 

Women, n (%)

6 (16.67)

9 (23.68)

6 (17.65)

 

Height (cm)

169.67 ± 7.32

167.68 ± 7.56

168.38 ± 7.07

0.503

Total body weight (kg)

87.11 ± 8.86

83.32 ± 7.29

84.18 ± 7.87

0.111

Ideal body weight (kg)

69.53 ± 7.46

67.05 ± 8.55

67.65 ± 7.31

0.372

Lean body weight (kg)

60.79 ± 5.97

57.77 ± 7.02

58.00 ± 6.24

0.089

BMI (kg/m2)

30.22 ± 1.84

29.61 ± 1.59

29.64 ± 1.48

0.211

ASA status:

   

0.254

I, n (%)

1 (2.78)

5 (13.16)

4 (11.76)

 

II, n (%)

35 (97.22)

33 (86.84)

30 (88.24)

 

Hypertension, n (%)

6 (16.67)

9 (23.68)

7 (20.59)

0.755

Diabetes, n (%)

5 (13.89)

2 (5.26)

1 (2.94)

0.178

Smoker, n (%)

27 (75.00)

25 (65.79)

25 (73.53)

0.642

Asthma, n (%)

0 (0.00)

0 (0.00)

1 (2.94)

0.333

Drinker:

   

0.420

Seldom, n (%)

28 (77.78)

33 (86.84)

30 (88.24)

 

Occasional, n (%)

8 (22.22)

5 (13.16)

4 (11.76)

 

SBQ:

   

0.406

≥3, n (%)

10 (27.78)

9 (23.68)

5 (14.71)

 

< 3, n (%)

26 (72.22)

29 (76.32)

29 (85.29)

 

Dose of dezocine (mg)

4.26 ± 0.54

4.04 ± 0.43

4.12 ± 0.44

0.152

Gastroscopy time (min)

8.00 ± 2.15

7.39 ± 1.59

6.91 ± 1.91

0.059

  1. Note: Data are presented as mean ± standard deviation or n. Data on frequency (percentage) were analysed using Pearson chi-squared test. The remaining data were analysed using the analysis of variance for group comparisons, and pairwise comparisons were conducted using the least significant difference test
  2. ASA, American Society of Anesthesiologists; BMI, body mass index; SBQ, STOP-BANG questionnaire